Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: A decision-analytic approach

Movement Disorders

Volumn 18, Issue SUPPL. 7, 2003, Pages

  Dodel, Richard C ^a   Höffken, Helmut ^b   Möller, J Carsten ^b   Bornschein, Bernhard ^a   Klockgether, Thomas ^a   Behr, Thomas ^b   Oertel, Wolfgang H ^b   Siebert, Uwe ^c,d  

^a UNIVERSITY OF BONN   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c HARVARD CENTER FOR RISK ANALYSIS   (United States)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

123I FP CIT SPECT; Cost; Cost effectiveness; Parkinson's disease; SPECT

Indexed keywords

DOPAMINE TRANSPORTER; IODINE 123; TRACER; TROPANE DERIVATIVE;

ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; MEDICAL DECISION MAKING; MODEL; MOTOR DYSFUNCTION; OUTPATIENT DEPARTMENT; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AMBULATORY CARE FACILITIES; BRAIN; COST-BENEFIT ANALYSIS; DECISION TREES; DIHYDROXYPHENYLALANINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GERMANY; HEALTH CARE COSTS; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NATIONAL HEALTH PROGRAMS; NERVE TISSUE PROTEINS; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PROSPECTIVE PAYMENT SYSTEM; REFERRAL AND CONSULTATION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0242288107     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10580     Document Type: Article

References (22)

1. 123I]β-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001;57:2089-2094.
2. 123I]β-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 2000;15:1158-1167.
3. 123I-β-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease. Mov Disord 1998;13:438-445.
4. 123I]β-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:294-298.
5. 123I]FP-CIT SPECT. J Nucl Med 1999;40:753-761.
6. Marsden CD, Parkes JD, Quinn NP. Fluctuations of disability in Parkinson's disease: clinical aspects. In: Marsden CD, Fahn S, Editors. Movement Disorders. London: Butterworth Scientific; 1982. p 96-122.
7. Hoehn M, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;427-442.
8. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999;28: 99-102.
9. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992;42:1142-1146.
10. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-870.
11. Hughes AJ, Daniel SE, Kilford L, Lees AJ. The accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
12. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001;57: 1497-1499.
13. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism - a prospective study. Can J Neurol Sci 1991;18: 275-278.
14. 123I]FP-CIT study group. Mov Disord 2000;15:503-510.
15. Anonymous. Gebührenordnung für Ärzte (GOÄ). Stuttgart: Nomos-Verlag; 2002.
16. Spottke EA, Reuther M, Athen O, et al. Healthcare utilization and economic impact of Parkinson's disease in Germany. Mov Disord 2002;17(Suppl.) 5:142.
17. Bundesverband der pharmazeutischen Industrie. Rote Liste. Weinheim: Rote Liste Verlag; 2002.
18. Gold M, Siegel J, Russell L, Weinstein M, eds. Cost-effectiveness in health and medicine. Oxford: University Press; 1996.
19. McMahon PM, Araki SS, Neumann PJ, Harris GJ, Gazelle GS. Cost-effectiveness of functional imaging tests in the diagnosis of Alzheimer disease. Radiology 2000;217:58-68.
20. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 2003;6:9-17.
21. Neumann PJ, Hammitt JK, Mueller C, Fillit HM, Hill J, Tetteh NA, Kosik KS. Public attitudes about genetic testing for Alzheimer's disease. Health Aff (Millwood) 2001;20:252-264.
22. Oertel WH, Quinn NP. Parkinsonism. In: Brandt T, Diener HC, Caplan LR, Kennard C, Dichgans J, Editors. Neurological disorders: course and treatment. San Diego: Academic Press; 2003. p 715-772.